Loading
Biotheus was a Chinese antibody company that developed PM8002 (BNT327, pumitamig), an antibody that blocks both PD-L1 and VEGF-A. BioNTech, already its partner on the drug, bought the company in early 2025.
Biotheus was a clinical-stage biotechnology company discovering and developing antibodies for cancer and inflammatory diseases; its announcement with BioNTech described several antibody discovery platforms and ten programmes in clinical development. Its leading asset, PM8002 (BNT327, later named pumitamig), is a bispecific antibody aimed at PD-L1 and VEGF-A, on which BioNTech and Biotheus were already collaborating. BioNTech agreed on 13 November 2024 to pay USD 800 million for all of Biotheus's issued share capital, plus up to USD 150 million in milestone payments, and completed the acquisition on 3 February 2025, when Biotheus became an indirect Chinese subsidiary of BioNTech with a research hub and a biologics manufacturing facility.
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Acquisition · BioNTech's announcement of 13 November 2024, filed as exhibit 99.1 to a BioNTech 6-K: USD 800 million for 100 percent of the issued share capital and up to USD 150 million in potential milestone payments; completed 3 February 2025 | 2024 | $800M | sec.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
PM8002 is an experimental bispecific antibody from Biotheus in phase 3 trials for small-cell lung cancer, triple-negative breast cancer and neuroendocrine tumours, aimed at PD-L1 and VEGF / VEGFR.
Shares VEGF / VEGFR, Bispecific antibodies, PD-L1.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/